BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 20502722)

  • 1. Zonisamide: a new drug for Parkinson's disease.
    Murata M
    Drugs Today (Barc); 2010 Apr; 46(4):251-8. PubMed ID: 20502722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease.
    Murata M
    Curr Pharm Des; 2004; 10(6):687-93. PubMed ID: 14965331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zonisamide suppresses endoplasmic reticulum stress-induced neuronal cell damage in vitro and in vivo.
    Tsujii S; Ishisaka M; Shimazawa M; Hashizume T; Hara H
    Eur J Pharmacol; 2015 Jan; 746():301-7. PubMed ID: 25261037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The discovery of an antiparkinsonian drug, zonisamide].
    Murata M
    Rinsho Shinkeigaku; 2010 Feb; 50(2):67-73. PubMed ID: 20196486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zonisamide for the treatment of Parkinson's disease.
    Miwa H
    Expert Rev Neurother; 2007 Sep; 7(9):1077-83. PubMed ID: 17868006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zonisamide: a review of the clinical and experimental evidence for its use in Parkinson's disease.
    Grover ND; Limaye RP; Gokhale DV; Patil TR
    Indian J Pharmacol; 2013; 45(6):547-55. PubMed ID: 24347760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zonisamide: aspects in neuroprotection.
    Rösler TW; Arias-Carrión O; Höglinger GU
    Exp Neurol; 2010 Aug; 224(2):336-9. PubMed ID: 20450911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotective effects of zonisamide target astrocyte.
    Asanuma M; Miyazaki I; Diaz-Corrales FJ; Kimoto N; Kikkawa Y; Takeshima M; Miyoshi K; Murata M
    Ann Neurol; 2010 Feb; 67(2):239-49. PubMed ID: 20225289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zonisamide has beneficial effects on Parkinson's disease patients.
    Murata M; Horiuchi E; Kanazawa I
    Neurosci Res; 2001 Dec; 41(4):397-9. PubMed ID: 11755227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapy of Parkinson's disease--up to date].
    Murata M
    Rinsho Shinkeigaku; 2008 Nov; 48(11):986-8. PubMed ID: 19198140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Discovery of an antiparkinsonian drug: zonisamide].
    Murata M
    Rinsho Shinkeigaku; 2010 Nov; 50(11):780-2. PubMed ID: 21921440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zonisamide: in Parkinson's disease.
    Yang LP; Perry CM
    CNS Drugs; 2009 Aug; 23(8):703-11. PubMed ID: 19594199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zonisamide: review of its use in epilepsy therapy.
    Zareba G
    Drugs Today (Barc); 2005 Sep; 41(9):589-97. PubMed ID: 16341290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination Therapy with Zonisamide and Antiparkinson Drugs for Parkinson's Disease: A Meta-Analysis.
    Matsunaga S; Kishi T; Iwata N
    J Alzheimers Dis; 2017; 56(4):1229-1239. PubMed ID: 28157097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zonisamide improves wearing-off in Parkinson's disease: A randomized, double-blind study.
    Murata M; Hasegawa K; Kanazawa I; Fukasaka J; Kochi K; Shimazu R;
    Mov Disord; 2015 Sep; 30(10):1343-50. PubMed ID: 26094993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zonisamide enhances delta receptor-associated neurotransmitter release in striato-pallidal pathway.
    Yamamura S; Ohoyama K; Nagase H; Okada M
    Neuropharmacology; 2009 Sep; 57(3):322-31. PubMed ID: 19482038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity.
    Marzo A; Dal Bo L; Monti NC; Crivelli F; Ismaili S; Caccia C; Cattaneo C; Fariello RG
    Pharmacol Res; 2004 Jul; 50(1):77-85. PubMed ID: 15082032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological therapy of Parkinson's disease: current options and new avenues.
    Simola N; Pinna A; Fenu S
    Recent Pat CNS Drug Discov; 2010 Nov; 5(3):221-38. PubMed ID: 20726838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zonisamide reduces nigrostriatal dopaminergic neurodegeneration in a mouse genetic model of Parkinson's disease.
    Sano H; Murata M; Nambu A
    J Neurochem; 2015 Jul; 134(2):371-81. PubMed ID: 25857446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.